BioNeutral Group, Inc. Redefining Important Multi-Billion Dollar Markets

[Guest guest]

BioNeutral Group, Inc. Redefining Important Multi-Billion Dollar

Markets

Ad-Hoc-News (Pressemitteilung) - Germany

BioNeutral Group, Inc. Redefining Important Multi-Billion Dollar

MarketsNEWARK, N.J.NJ-BIONEUTRAL-GROUP

http://www.ad-hoc-news.de/bioneutral-group-inc-redefining-important-

multi-billion--/de/Unternehmensnachrichten/20067571

NEWARK, N.J.--(BUSINESS WIRE)--

BioNeutral Group, Inc. (OTCBB: BONU), a chemical technology-based

Life Science company intends to commercialize one of the most

important advances in disinfectants in the past two decades.

BioNeutral has developed a family of disinfectants which have been

described as unequaled in the known field of chemistry. One of the

formulations, Ygiene? operates unlike any competitive product on the

market. Ygiene? kills all bacteria, virus, fungi, mold and spores

quickly and without exception. The Company intends to market its

formulations to the military, healthcare, consumer and industrial

sectors which represent a combined annual multi-billion dollar

market.

Markets which are dominated by relatively few major players are not

easily susceptible to dislocation because they have the market, the

money, the channels of distribution and the advertising budget to

market and sell their products. One of the few ways a dislocation can

take place is through an advance in technology which has a vital and

significant benefit for the end user. BioNeutral believes its ground-

breaking technology can be described as the most advanced discovery

in two decades in this market place.

BioNeutral has two different technology platforms which underpin

Ygiene? and Ogiene? formulations. The formulations are eco-friendly

and include natural and common ingredients which are found in baby

products and in everyday foods. The formulations are stable, non-

corrosive, non-flammable and water soluble and can be applied as a

liquid, wet wipe, spray, mist/fog or foam/froth. BioNeutral?s

proprietary platform technology has been proven effective in surface,

water and airborne applications.

BioNeutralizers are based on the proprietary Ygiene? platform

formulation which disinfect, decontaminate and sterilizes. Ygiene? is

peroxy-based and can deliver more active ingredient than any

currently available antimicrobial; it has been proven to kill health

threatening spores on contact including Anthrax, Clostridium

difficile and Black Mold.

ChemoNeutralizers are based on the proprietary Ogiene? platform

formulation which irreversibly binds chemical contaminants and toxin

molecules to render them harmless. Ogiene? formulation interacts with

the functional organic or inorganic groups of harmful gases removing

them from the air; it can accelerate the conversion of toxic and

noxious gases neutralizing them and rendering them harmless. Toxic

gases and odors eliminated or dramatically reduced using Ogiene?

formulations include formaldehyde, ammonia and carbon dioxide, sulfur

dioxide and nitrogen oxide (greenhouse gases) and smoke from the

burning of fossil fuels including tobacco. Product applications

include industrial pollution, environmental contaminants, and

protection against chemical weapons of mass destruction. Ogiene

formulations have exceptional stain removing capabilities and have

been tested and found superior to competitive products on the market.

J. Browand, President and CEO of BioNeutral Group, Inc.

said, ?We believe we have the broadest-based, fastest acting and most

effective antimicrobial known and we intend to become a leading

company in some very large markets. Our goals are clear and we plan

to keep our shareholders and the financial community well informed on

our progress in the coming months.?

About BioNeutral Group, Inc.

Headquartered at the New Jersey Institute of Technology/EDC in

Newark, New Jersey, BioNeutral Group, Inc., is a specialty Life

Science company that intends to commercialize a novel combinational

chemistry-based technology which can neutralize harmful environmental

contaminants, toxins and dangerous micro-organisms including

bacteria, viruses, mold, fungi and spores. The formulations,

including Ygiene? and Ogiene?, which are eco-friendly and include

natural and common ingredients which are found in baby products and

in every day foods. The Company has combined these widely-used

compounds in highly specialized ways to create products that

dramatically enhance disinfecting and cleaning results; products

include BioNeutralizers and ChemoNeutralizers. BioNeutral?s

proprietary platform technology has been proven effective in surface,

water and airborne applications.

More information about the Company may be found at

www.bioneutralgroup.com

Forward-Looking Statements

BioNeutral routinely tests its formulations against those of its

competitors. The results are published to let shareholders know how

the Company's technology compares with known formulations in the

market place. Any product claim for antimicrobial activity requires

approval from the EPA or FDA, depending upon where and how the

formulations are used. The EPA and FDA have not reviewed or confirmed

the Company's data and findings. BioNeutral's antimicrobial

formulations will be marketed under the brand name Ygiene? and are

not yet available for sale in the Untied States.

Under The Private Securities Litigation Reform Act of 1995: The

statements in the press release that relate to the Company's

expectations with regard to the future impact on the Company's

results from new products in development are forward-looking

statements within the meaning of the Private Securities Litigation

Reform Act of 1995. These statements are subject to risks and

uncertainties. Words such

as " expects " , " intends " , " plans " , " may " , " could " , " should " , " anticipat

es " , " likely " , " believes " and words of similar import also identify

forward-looking statements. Forward-looking statements are based on

current facts and analyses and other information that are based on

forecasts of future results, estimates of amounts not yet determined

and assumptions of management. Readers are urged not to place undue

reliance on the forward-looking statements, which speak only as of

the date of this release. We assume no obligation to update any

forward-looking statements in order to reflect any event or

circumstance that may arise after the date of this release.

Additional information on risks and other factors that may affect the

business and financial results of BioNeutral Group can be found in

the filings of BioNeutral Group with the U.S. Securities and Exchange

Commission.

Url zum Artikel: http://www.ad-hoc-news.de/bioneutral-group-inc-

redefining-important-multi-billion--/de/Unternehmensnachrichten/

[Guest guest]

would love to know what Carl, Jeff, and Doug think about this product?

tigerpaw2c <tigerpaw2c@...> wrote: BioNeutral

Group, Inc. Redefining Important Multi-Billion Dollar

Markets

Ad-Hoc-News (Pressemitteilung) - Germany

BioNeutral Group, Inc. Redefining Important Multi-Billion Dollar

MarketsNEWARK, N.J.NJ-BIONEUTRAL-GROUP

http://www.ad-hoc-news.de/bioneutral-group-inc-redefining-important-

multi-billion--/de/Unternehmensnachrichten/20067571

NEWARK, N.J.--(BUSINESS WIRE)--

BioNeutral Group, Inc. (OTCBB: BONU), a chemical technology-based

Life Science company intends to commercialize one of the most

important advances in disinfectants in the past two decades.

BioNeutral has developed a family of disinfectants which have been

described as unequaled in the known field of chemistry. One of the

formulations, Ygiene? operates unlike any competitive product on the

market. Ygiene? kills all bacteria, virus, fungi, mold and spores

quickly and without exception. The Company intends to market its

formulations to the military, healthcare, consumer and industrial

sectors which represent a combined annual multi-billion dollar

market.

Markets which are dominated by relatively few major players are not

easily susceptible to dislocation because they have the market, the

money, the channels of distribution and the advertising budget to

market and sell their products. One of the few ways a dislocation can

take place is through an advance in technology which has a vital and

significant benefit for the end user. BioNeutral believes its ground-

breaking technology can be described as the most advanced discovery

in two decades in this market place.

BioNeutral has two different technology platforms which underpin

Ygiene? and Ogiene? formulations. The formulations are eco-friendly

and include natural and common ingredients which are found in baby

products and in everyday foods. The formulations are stable, non-

corrosive, non-flammable and water soluble and can be applied as a

liquid, wet wipe, spray, mist/fog or foam/froth. BioNeutral?s

proprietary platform technology has been proven effective in surface,

water and airborne applications.

BioNeutralizers are based on the proprietary Ygiene? platform

formulation which disinfect, decontaminate and sterilizes. Ygiene? is

peroxy-based and can deliver more active ingredient than any

currently available antimicrobial; it has been proven to kill health

threatening spores on contact including Anthrax, Clostridium

difficile and Black Mold.

ChemoNeutralizers are based on the proprietary Ogiene? platform

formulation which irreversibly binds chemical contaminants and toxin

molecules to render them harmless. Ogiene? formulation interacts with

the functional organic or inorganic groups of harmful gases removing

them from the air; it can accelerate the conversion of toxic and

noxious gases neutralizing them and rendering them harmless. Toxic

gases and odors eliminated or dramatically reduced using Ogiene?

formulations include formaldehyde, ammonia and carbon dioxide, sulfur

dioxide and nitrogen oxide (greenhouse gases) and smoke from the

burning of fossil fuels including tobacco. Product applications

include industrial pollution, environmental contaminants, and

protection against chemical weapons of mass destruction. Ogiene

formulations have exceptional stain removing capabilities and have

been tested and found superior to competitive products on the market.

J. Browand, President and CEO of BioNeutral Group, Inc.

said, ?We believe we have the broadest-based, fastest acting and most

effective antimicrobial known and we intend to become a leading

company in some very large markets. Our goals are clear and we plan

to keep our shareholders and the financial community well informed on

our progress in the coming months.?

About BioNeutral Group, Inc.

Headquartered at the New Jersey Institute of Technology/EDC in

Newark, New Jersey, BioNeutral Group, Inc., is a specialty Life

Science company that intends to commercialize a novel combinational

chemistry-based technology which can neutralize harmful environmental

contaminants, toxins and dangerous micro-organisms including

bacteria, viruses, mold, fungi and spores. The formulations,

including Ygiene? and Ogiene?, which are eco-friendly and include

natural and common ingredients which are found in baby products and

in every day foods. The Company has combined these widely-used

compounds in highly specialized ways to create products that

dramatically enhance disinfecting and cleaning results; products

include BioNeutralizers and ChemoNeutralizers. BioNeutral?s

proprietary platform technology has been proven effective in surface,

water and airborne applications.

More information about the Company may be found at

www.bioneutralgroup.com

Forward-Looking Statements

BioNeutral routinely tests its formulations against those of its

competitors. The results are published to let shareholders know how

the Company's technology compares with known formulations in the

market place. Any product claim for antimicrobial activity requires

approval from the EPA or FDA, depending upon where and how the

formulations are used. The EPA and FDA have not reviewed or confirmed

the Company's data and findings. BioNeutral's antimicrobial

formulations will be marketed under the brand name Ygiene? and are

not yet available for sale in the Untied States.

Under The Private Securities Litigation Reform Act of 1995: The

statements in the press release that relate to the Company's

expectations with regard to the future impact on the Company's

results from new products in development are forward-looking

statements within the meaning of the Private Securities Litigation

Reform Act of 1995. These statements are subject to risks and

uncertainties. Words such

as " expects " , " intends " , " plans " , " may " , " could " , " should " , " anticipat

es " , " likely " , " believes " and words of similar import also identify

forward-looking statements. Forward-looking statements are based on

current facts and analyses and other information that are based on

forecasts of future results, estimates of amounts not yet determined

and assumptions of management. Readers are urged not to place undue

reliance on the forward-looking statements, which speak only as of

the date of this release. We assume no obligation to update any

forward-looking statements in order to reflect any event or

circumstance that may arise after the date of this release.

Additional information on risks and other factors that may affect the

business and financial results of BioNeutral Group can be found in

the filings of BioNeutral Group with the U.S. Securities and Exchange

Commission.

Url zum Artikel: http://www.ad-hoc-news.de/bioneutral-group-inc-

redefining-important-multi-billion--/de/Unternehmensnachrichten/